POM-V Prescription Required Companion Animal

Bonqat 50 mg/ml Oral Solution for Cats

Active ingredient: Pregabalin

Form

Liquid

Species

Cats

Manufacturer

Orion Corporation

VMD MA No.

06043/5003

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Pregabalin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bonqat 50 mg/ml Oral Solution for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

The veterinary medicinal product is administered orally as a single dose of 5 mg/kg
bodyweight (0.1 ml/kg bw) approximately 1.5 hours before the start of the
transportation/planned veterinary visit.

Amended pages: August 2025
The veterinary medicinal product can be administered either directly into the mouth
or mixed with a small amount of food. Large amounts of food may delay the onset of
effect.
Use the oral syringe provided in the package for administration of the veterinary
medicinal product.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cats:
Common
(1 to 10 animals / 100 animals treated):
Emesis
Ataxia, Sedation, Proprioception
abnormality
Lethargy
Uncommon
(1 to 10 animals / 1 000 animals
treated):
Leucopenia
Muscle tremor, Mydriasis
Anorexia, Weight loss
Rare
(1 to 10 animals / 10 000 animals
treated):
Salivation
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Amended pages: August 2025

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in cats
weighing less than 2 kg, younger than 5 months and older than 15 years. Use only
according to the benefit-risk assessment by the responsible veterinarian.
The safety of the veterinary medicinal product has only been established in healthy
cats or those with mild systemic illness. It has not been established in animals with
moderate or severe systemic disease e.g. moderate to severe renal, liver, or
cardiovascular disease. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Always assess the cat’s health status before prescribing the veterinary medicinal
product.
The veterinary medicinal product may cause slight reduction in heart rate, respiratory
rate and body temperature. As a reduction of body temperature can occur after the
administration, the treated animal should be kept at a suitable ambient temperature.
Monitor the cat carefully for any symptoms of respiratory depression and sedation
when a CNS depressant is used concomitantly with pregabalin.
The prescribing veterinarian should advise the owner to always inform the attending
veterinarian if the veterinary medicinal product has been administered to the cat prior
to the veterinary visit.
If the cat spits part of the dose, vomits after treatment, or in case of hypersalivation,
do not give another dose.
The effect of the veterinary medicinal product can last approximately 7 hours. In case
the cat seems drowsy or shows other signs of exaggerated effects after treatment
administration, keep the cat indoors and do not offer water or feed until the cat has
fully recovered.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Exposure to pregabalin may cause adverse effects such as dizziness, tiredness,
ataxia, blurred vision and headache.
Avoid skin, eye or mucosal contact. Thoroughly wash hands immediately after
administration of the veterinary medicinal product.
In case of accidental eye or mucosal contact, flush with water. Seek medical advice if
symptoms (dizziness, tiredness, ataxia or blurred vision) occur.
In case of skin contact, wash with soap and water. Remove contaminated clothing.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician. Do not drive as tiredness may occur.

Amended pages: August 2025
Special precautions for the protection of the environment:
Not applicable.

The use of other central nervous system depressants is expected to potentiate the
effects of pregabalin and therefore an appropriate dose adjustment should be made.

Store in a refrigerator (2 °C–8 °C).

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.